title: [Analysis of hypertension in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab].
abstract: OBJECTIVE
  The aim of this study was to retrospectively assess if arterial hypertension induced during treatment with bevacizumab was associated with the clinical outcome in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab.
  
  
  METHODS
  13 patients( 7 men and 6 women) with advanced, recurrent colorectal cancer were treated by mFOLFOX6 regimen with first-line bevacizumab from August 2008 to July 2009. The median age was 64. 4 years (51 to 79 years old) with 10 and 3 patients having a PS score of 0 and 1. All patients received bevacizumab at a dose of 5 mg/kg every 2 weeks in association with oxaliplatin, 5-fluorouracil and folinic acid according to the mFOLFOX6 regimen.
  
  
  RESULTS
  9 patients (69. 0%) had hypertension, while 5 patients developed grades 2-3 hypertension on bevacizumab. Patients with hypertension tended to have a better response rate and disease control rate than patients without hypertension.
  
  
  CONCLUSIONS
  Bevacizumab-induced hypertension may represent a prognostic factor for clinical outcome in advanced, recurrent colorectal cancer patients treated with first-line bevacizumab.
authors.affiliation: Dept. of Surgery, Konan Kosei Hospital.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yamamura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ishigure
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab